

# Krista L Lentine

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6904356/publications.pdf>

Version: 2024-02-01

333  
papers

13,826  
citations

30551

56  
h-index

36203

101  
g-index

343  
all docs

343  
docs citations

343  
times ranked

11510  
citing authors

#	ARTICLE	IF	CITATIONS
1	Incidence, Clinical Correlates, and Outcomes of Pulmonary Hypertension After Kidney Transplantation: Analysis of Linked US Registry and Medicare Billing Claims. <i>Transplantation</i> , 2022, 106, 666-675.	0.5	3
2	The Clinical and Economic Benefit of CMV Matching in Kidney Transplant: A Decision Analysis. <i>Transplantation</i> , 2022, 106, 1227-1232.	0.5	7
3	Posttransplant Diabetes Mellitus and Immunosuppression Selection in Older and Obese Kidney Recipients. <i>Kidney Medicine</i> , 2022, 4, 100377.	1.0	10
4	Oxidative stress and macrophage infiltration in IgA nephropathy. <i>Journal of Nephrology</i> , 2022, 35, 1101-1111.	0.9	7
5	COVID-19 vaccination timing and kidney transplant waitlist management: An international perspective. <i>Transplant Infectious Disease</i> , 2022, 24, e13763.	0.7	8
6	Silent myocardial infarction on preoperative electrocardiogram for kidney transplant patients: Impact on clinical outcomes may not be silent. <i>American Journal of Transplantation</i> , 2022, , .	2.6	1
7	Approach to genetic testing to optimize the safety of living donor transplantation in Alport syndrome spectrum. <i>Pediatric Nephrology</i> , 2022, 37, 1981-1994.	0.9	4
8	Understanding and Overcoming Financial Risks for Living Organ Donors. <i>American Journal of Kidney Diseases</i> , 2022, 79, 159-161.	2.1	5
9	Survey of current transplant center practices regarding COVID-19 vaccine mandates in the United States. <i>American Journal of Transplantation</i> , 2022, 22, 1705-1713.	2.6	32
10	Deceased Donor Procurement Biopsy Practices, Interpretation, and Histology-Based Decision-Making: A Survey of US Kidney Transplant Centers. <i>Kidney International Reports</i> , 2022, 7, 1268-1277.	0.4	5
11	Associations of Lack of Insurance and Other Sociodemographic Traits With Follow-up After Living Kidney Donation. <i>American Journal of Kidney Diseases</i> , 2022, 80, 683-685.	2.1	2
12	Evaluation of Genetic Kidney Diseases in Living Donor Kidney Transplantation: Towards Precision Genomic Medicine in Donor Risk Assessment. <i>Current Transplantation Reports</i> , 2022, 9, 127-142.	0.9	8
13	Solid Organ Transplantation in SARS-CoV-2 Recovered Transplant Candidates: a Comprehensive Review of Recent Literature. <i>Current Transplantation Reports</i> , 2022, 9, 95-107.	0.9	10
14	Effect of Early Steroid Withdrawal on Posttransplant Diabetes Among Kidney Transplant Recipients Differs by Recipient Age. <i>Transplantation Direct</i> , 2022, 8, e1260.	0.8	5
15	Kidney Transplantation, Immunosuppression, and Fracture Risk: Clinical and Economic Implications. <i>Kidney Medicine</i> , 2022, , 100474.	1.0	1
16	Exacerbation of Racial Disparities in Living Donor Kidney Transplantation During the COVID-19 Pandemic. <i>Kidney360</i> , 2022, 3, 1089-1094.	0.9	6
17	Telemedicine services for living kidney donation: A US survey of multidisciplinary providers. <i>American Journal of Transplantation</i> , 2022, 22, 2041-2051.	2.6	6
18	Using race to estimate glomerular filtration and its impact in kidney transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14136.	0.8	20

#	ARTICLE	IF	CITATIONS
19	An International survey on living kidney donation and transplant practices during the COVID-19 pandemic. <i>Transplant Infectious Disease</i> , 2021, 23, e13526.	0.7	31
20	A simple risk-based reimbursement system for kidney transplant. <i>Clinical Transplantation</i> , 2021, 35, e14068.	0.8	5
21	Approach to pancreas transplant during the COVID-19 pandemic. <i>Clinical Transplantation</i> , 2021, 35, e14177.	0.8	3
22	OPTN/SRTR 2019 Annual Data Report: Econ. <i>American Journal of Transplantation</i> , 2021, 21, 521-566.	2.6	8
23	OPTN/SRTR 2019 Annual Data Report: Kidney. <i>American Journal of Transplantation</i> , 2021, 21, 21-137.	2.6	283
24	High-dose opioid utilization and mortality among individuals initiating hemodialysis. <i>BMC Nephrology</i> , 2021, 22, 65.	0.8	3
25	COVID-19 test result reporting for deceased donors: Emergent policies, logistical challenges, and future directions. <i>Clinical Transplantation</i> , 2021, 35, e14280.	0.8	7
26	Kidney recipients with allograft failure, transition of kidney care (KRAFT): A survey of contemporary practices of transplant providers. <i>American Journal of Transplantation</i> , 2021, 21, 3034-3042.	2.6	23
27	Outcomes of Living Kidney Donor Candidate Evaluations in the Living Donor Collective Pilot Registry. <i>Transplantation Direct</i> , 2021, 7, e689.	0.8	16
28	Living Organ Donor Perspectives and Sources of Hesitancy about COVID-19 Vaccines. <i>Kidney360</i> , 2021, 2, 1132-1140.	0.9	3
29	LIMS1 risk genotype and T cell-mediated rejection in kidney transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2021, 36, 2120-2129.	0.4	8
30	Immunosuppression Considerations for Older Kidney Transplant Recipients. <i>Current Transplantation Reports</i> , 2021, 8, 100-110.	0.9	16
31	Procurement Biopsies in Kidney Transplantation: More Information May Not Lead to Better Decisions. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1835-1837.	3.0	13
32	Practicing With Uncertainty: Kidney Transplantation During the COVID-19 Pandemic. <i>American Journal of Kidney Diseases</i> , 2021, 77, 777-785.	2.1	39
33	Survival implications of prescription opioid and benzodiazepine use in lung transplant recipients: Analysis of linked transplant registry and pharmacy fill records. <i>Journal of Heart and Lung Transplantation</i> , 2021, 40, 513-524.	0.3	7
34	The Risk of Postkidney Transplant Outcomes by Induction Choice Differs by Recipient Age. <i>Transplantation Direct</i> , 2021, 7, e715.	0.8	5
35	Renal Considerations in COVID-19: Biology, Pathology, and Pathophysiology. <i>ASAIO Journal</i> , 2021, 67, 1087-1096.	0.9	5
36	Solid organ transplantation during the COVID-19 pandemic in the United States. <i>Transplant International</i> , 2021, 34, 1319-1321.	0.8	4

#	ARTICLE	IF	CITATIONS
37	NSAID prescriptions in kidney transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14405.	0.8	7
38	Frailty, Age, and Postdialysis Recovery Time in a Population New to Hemodialysis. <i>Kidney360</i> , 2021, 2, 1455-1462.	0.9	5
39	Eliminating racial disparities in kidney transplantation. <i>Clinical Transplantation</i> , 2021, 35, e14397.	0.8	7
40	Simultaneous Pancreas-kidney Transplantation for Type 2 Diabetes Mellitus. <i>Transplantation</i> , 2021, 105, e91-e92.	0.5	5
41	Operational challenges in the COVID-19 era: Asymptomatic infections and vaccination timing. <i>Clinical Transplantation</i> , 2021, 35, e14437.	0.8	16
42	The failing kidney allograft: A review and recommendations for the care and management of a complex group of patients. <i>American Journal of Transplantation</i> , 2021, 21, 2937-2949.	2.6	24
43	Immunosuppression Regimen Use and Outcomes in Older and Younger Adult Kidney Transplant Recipients: A National Registry Analysis. <i>Transplantation</i> , 2021, 105, 1840-1849.	0.5	22
44	Clinical Correlates and Outcomes of Dual Basiliximab and Antithymocyte Globulin Induction in Kidney Transplant Recipients: A National Study. <i>Transplantation Direct</i> , 2021, 7, e736.	0.8	3
45	Pancreas transplantation perceptions and practice: Results from a national US survey. <i>Clinical Transplantation</i> , 2021, 35, e14432.	0.8	6
46	Maximizing the use of hard to place kidneys: Getting the right kidney to the right recipient at the right time. <i>American Journal of Transplantation</i> , 2021, 21, 3516-3518.	2.6	4
47	A National Survey of Practice Patterns for Accepting Living Kidney Donors With Prior COVID-19. <i>Kidney International Reports</i> , 2021, 6, 2066-2074.	0.4	3
48	Disparities in Deceased Organ Donor Research Authorization: Experience at One Organ Procurement Organization and Call for National Conversations. <i>Kidney International Reports</i> , 2021, 6, 2331-2337.	0.4	2
49	A Roadmap for Innovation to Advance Transplant Access and Outcomes: A Position Statement From the National Kidney Foundation. <i>American Journal of Kidney Diseases</i> , 2021, 78, 319-332.	2.1	21
50	Opioids and Kidney Transplantation. <i>Seminars in Nephrology</i> , 2021, 41, 42-53.	0.6	3
51	Trends in Discard of Kidneys from Hepatitis C Viremic Donors in the United States. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 251-261.	2.2	20
52	Early Changes in Kidney Transplant Immunosuppression Regimens During the COVID-19 Pandemic. <i>Transplantation</i> , 2021, 105, 170-176.	0.5	37
53	Use of Organs from SARS-CoV-2 Infected Donors: Is It Safe? A Contemporary Review. <i>Current Transplantation Reports</i> , 2021, 8, 281-292.	0.9	38
54	Clinician and patient attitudes toward use of organs from hepatitis C viremic donors and their impact on acceptance: A contemporary review. <i>Clinical Transplantation</i> , 2021, 35, e14519.	0.8	3

#	ARTICLE	IF	CITATIONS
55	Transplant Clinician Opinions on Use of Race in the Estimation of Glomerular Filtration Rate. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2021, 16, 1552-1559.	2.2	17
56	Association of Ambient Fine Particulate Matter Air Pollution With Kidney Transplant Outcomes. <i>JAMA Network Open</i> , 2021, 4, e2128190.	2.8	9
57	Reducing Kidney Discard With Artificial Intelligence Decision Support: the Need for a Transdisciplinary Systems Approach. <i>Current Transplantation Reports</i> , 2021, 8, 263-271.	0.9	8
58	Living donor program crisis management plans: Current landscape and talking point recommendations. <i>American Journal of Transplantation</i> , 2020, 20, 546-552.	2.6	9
59	Three-month pancreas graft function significantly influences survival following simultaneous pancreas-kidney transplantation in type 2 diabetes patients. <i>American Journal of Transplantation</i> , 2020, 20, 788-796.	2.6	28
60	Donor-Recipient Relationship and Risk of ESKD in Live Kidney Donors of Varied Racial Groups. <i>American Journal of Kidney Diseases</i> , 2020, 75, 333-341.	2.1	19
61	APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO): Design and Rationale. <i>Kidney International Reports</i> , 2020, 5, 278-288.	0.4	62
62	Perceptions and Practices Regarding Frailty in Kidney Transplantation: Results of a National Survey. <i>Transplantation</i> , 2020, 104, 349-356.	0.5	54
63	Education Strategies in Dialysis Centers Associated With Increased Transplant Wait-listing Rates. <i>Transplantation</i> , 2020, 104, 335-342.	0.5	23
64	Induction immunosuppression and the risk of incident malignancies among older and younger kidney transplant recipients: A prospective cohort study. <i>Clinical Transplantation</i> , 2020, 34, e14121.	0.8	8
65	Hydroxychloroquine and maintenance immunosuppression use in kidney transplant recipients: Analysis of linked US registry and claims data. <i>Clinical Transplantation</i> , 2020, 34, e14118.	0.8	4
66	Integrated Risk Assessment Versus Age-Specific GFR Thresholds for Living Donor Candidate Evaluation. <i>Transplantation</i> , 2020, 104, 2464-2466.	0.5	3
67	Care of international living kidney donor candidates in the United States: A survey of contemporary experience, practice, and challenges. <i>Clinical Transplantation</i> , 2020, 34, e14064.	0.8	10
68	Incidence, Risk Factors, and Outcomes of Kidney Transplant Recipients Treated With Both Basiliximab and Antithymocyte Globulin. <i>Canadian Journal of Kidney Health and Disease</i> , 2020, 7, 205435812096406.	0.6	1
69	Apolipoprotein L1: role in the evaluation of kidney transplant donors. <i>Current Opinion in Nephrology and Hypertension</i> , 2020, 29, 645-655.	1.0	18
70	Survey of US Living Kidney Donation and Transplantation Practices in the COVID-19 Era. <i>Kidney International Reports</i> , 2020, 5, 1894-1905.	0.4	54
71	The kidney evaluation of living kidney donor candidates: US practices in 2017. <i>American Journal of Transplantation</i> , 2020, 20, 3379-3389.	2.6	29
72	Metabolic, cardiovascular, and substance use evaluation of living kidney donor candidates: US practices in 2017. <i>American Journal of Transplantation</i> , 2020, 20, 3390-3400.	2.6	21

#	ARTICLE	IF	CITATIONS
73	Association of Socioeconomic Status and Comorbidities with Racial Disparities during Kidney Transplant Evaluation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 843-851.	2.2	27
74	Long-term renal function in living kidney donors with simple renal cysts: A retrospective cohort study. <i>Clinical Transplantation</i> , 2020, 34, e13905.	0.8	3
75	Early Steroid Withdrawal in Deceased-Donor Kidney Transplant Recipients with Delayed Graft Function. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 175-185.	3.0	20
76	Benzodiazepines, Codispensed Opioids, and Mortality among Patients Initiating Long-Term In-Center Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 794-804.	2.2	11
77	Patient and Kidney Allograft Survival with National Kidney Paired Donation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 228-237.	2.2	25
78	Measuring Quality in Kidney Care: An Evaluation of Existing Quality Metrics and Approach to Facilitating Improvements in Care Delivery. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 602-614.	3.0	28
79	Outcome implications of benzodiazepine and opioid co-prescription in kidney transplant recipients. <i>Clinical Transplantation</i> , 2020, 34, e14005.	0.8	6
80	Changes in kidney function follow living donor nephrectomy. <i>Kidney International</i> , 2020, 98, 176-186.	2.6	41
81	Prescription patterns of opioids and non-steroidal anti-inflammatory drugs in the first year after living kidney donation: An analysis of U.S. Registry and Pharmacy fill records. <i>Clinical Transplantation</i> , 2020, 34, e14000.	0.8	4
82	An overview of frailty in kidney transplantation: measurement, management and future considerations. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 1099-1112.	0.4	68
83	Evaluating multiple living kidney donor candidates simultaneously is more cost-effective than sequentially. <i>Kidney International</i> , 2020, 98, 1578-1588.	2.6	6
84	Economic impacts of alternative kidney transplant immunosuppression: A national cohort study. <i>Clinical Transplantation</i> , 2020, 34, e13813.	0.8	2
85	Evaluation and care of international living kidney donor candidates: Strategies for addressing common considerations and challenges. <i>Clinical Transplantation</i> , 2020, 34, e13792.	0.8	8
86	Association of Early Postdonation Renal Function With Subsequent Risk of End-Stage Renal Disease in Living Kidney Donors. <i>JAMA Surgery</i> , 2020, 155, e195472.	2.2	32
87	Impacts of center and clinical factors in antihypertensive medication use after kidney transplantation. <i>Clinical Transplantation</i> , 2020, 34, e13803.	0.8	2
88	Application of the 2017 KDIGO Guideline for the Evaluation and Care of Living Kidney Donors to Clinical Practice. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 896-905.	2.2	19
89	The Cost of Screening Kidney Transplant Candidates for Coronary Artery Disease. <i>American Journal of Kidney Diseases</i> , 2020, 75, 684-686.	2.1	5
90	Impact of ABO-Incompatible Living Donor Kidney Transplantation on Patient Survival. <i>American Journal of Kidney Diseases</i> , 2020, 76, 616-623.	2.1	25

#	ARTICLE	IF	CITATIONS
91	Impact of Functional Status on Outcomes of Simultaneous Pancreas-kidney Transplantation: Risks and Opportunities for Patient Benefit. <i>Transplantation Direct</i> , 2020, 6, e599.	0.8	15
92	Financial Evaluation of Kidney Transplant With Hepatitis C Viremic Donors to Uninfected Recipients. <i>Transplantation Direct</i> , 2020, 6, e627.	0.8	4
93	The Advancing American Kidney Health (AAKH) Executive Order: Promise and Caveats for Expanding Access to Kidney Transplantation. <i>Kidney360</i> , 2020, 1, 557-560.	0.9	23
94	Survey of Clinician Opinions on Kidney Transplantation from Hepatitis C Virus Positive Donors: Identifying and Overcoming Barriers. <i>Kidney360</i> , 2020, 1, 1291-1299.	0.9	25
95	THE RISK OF POST-KT OUTCOMES BY INDUCTION CHOICE DIFFER BETWEEN OLDER AND YOUNGER KT RECIPIENTS. <i>Transplantation</i> , 2020, 104, S33-S33.	0.5	0
96	Use of Twitter in communicating living solid organ donation information to the public: An exploratory study of living donors and transplant professionals. <i>Clinical Transplantation</i> , 2019, 33, e13447.	0.8	13
97	Perioperative Complications During Living Donor Nephrectomy: Results From a Multicenter Cohort Study. <i>Canadian Journal of Kidney Health and Disease</i> , 2019, 6, 205435811985771.	0.6	17
98	Prescription opioid use before and after heart transplant: Associations with posttransplant outcomes. <i>American Journal of Transplantation</i> , 2019, 19, 3405-3414.	2.6	12
99	Associations of obesity with antidiabetic medication use after living kidney donation: An analysis of linked national registry and pharmacy fill records. <i>Clinical Transplantation</i> , 2019, 33, e13696.	0.8	13
100	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 96, 836-849.	2.6	80
101	Chronic Kidney Disease and Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 1823-1838.	1.2	403
102	Self-Reported Incident Hypertension and Long-Term Kidney Function in Living Kidney Donors Compared with Healthy Nondonors. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 1493-1499.	2.2	39
103	Billing for Living Kidney Donor Care: Balancing Cost Recovery, Regulatory Compliance, and Minimized Donor Burden. <i>Current Transplantation Reports</i> , 2019, 6, 155-166.	0.9	17
104	Modeling the economic benefit of targeted mild hypothermia in deceased donor kidney transplantation. <i>Clinical Transplantation</i> , 2019, 33, e13626.	0.8	7
105	Early Hypertension and Diabetes After Living Kidney Donation: A National Cohort Study. <i>Transplantation</i> , 2019, 103, 1216-1223.	0.5	20
106	Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <i>Kidney International</i> , 2019, 95, 1304-1317.	2.6	232
107	Frailty and Access to Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2019, 14, 576-582.	2.2	89
108	Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association. <i>Circulation</i> , 2019, 139, e840-e878.	1.6	619

#	ARTICLE	IF	CITATIONS
109	Risks of Living Kidney Donation. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 597-608.	2.2	101
110	Implications of Frailty for Peritransplant Outcomes in Kidney Transplant Recipients. Current Transplantation Reports, 2019, 6, 16-25.	0.9	30
111	Outcomes Following Macrolide Use in Kidney Transplant Recipients. Canadian Journal of Kidney Health and Disease, 2019, 6, 205435811983070.	0.6	9
112	Variation in use of procurement biopsies and its implications for discard of deceased donor kidneys recovered for transplantation. American Journal of Transplantation, 2019, 19, 2241-2251.	2.6	37
113	Racial/Ethnic Disparities in Access and Outcomes of Simultaneous Liver-Kidney Transplant Among Liver Transplant Candidates With Renal Dysfunction in the United States. Transplantation, 2019, 103, 1663-1674.	0.5	9
114	Cannabis Dependence or Abuse in Kidney Transplantation: Implications for Posttransplant Outcomes. Transplantation, 2019, 103, 2373-2382.	0.5	36
115	Postdonation eGFR and New-Onset Antihypertensive Medication Use After Living Kidney Donation. Transplantation Direct, 2019, 5, e474.	0.8	4
116	The Epidemiology, Outcomes, and Costs of Contemporary Kidney Transplantation. , 2019, , 539-554.e5.		10
117	The landscape of international living kidney donation in the United States. American Journal of Transplantation, 2019, 19, 2009-2019.	2.6	18
118	Induction immunosuppression agents as risk factors for incident cardiovascular events and mortality after kidney transplantation. American Journal of Transplantation, 2019, 19, 1150-1159.	2.6	8
119	How Should Social Media Be Used in Transplantation? A Survey of the American Society of Transplant Surgeons. Transplantation, 2019, 103, 573-580.	0.5	29
120	Cannabis Dependence or Abuse in Kidney Transplantation. Transplantation, 2019, 103, 1.	0.5	0
121	An economic assessment of contemporary kidney transplant practice. American Journal of Transplantation, 2018, 18, 1168-1176.	2.6	250
122	Establishing a Core Outcome Measure for Graft Health. Transplantation, 2018, 102, 1358-1366.	0.5	18
123	Transplant recipients are vulnerable to coverage denial under Medicare Part D. American Journal of Transplantation, 2018, 18, 1502-1509.	2.6	18
124	Assessment of Glomerular Filtration Rate and End-Stage Kidney Disease Risk in Living Kidney Donor Candidates: A Paradigm for Evaluation, Selection, and Counseling. Advances in Chronic Kidney Disease, 2018, 25, 21-30.	0.6	12
125	OPTN/SRTR 2016 Annual Data Report: Economics. American Journal of Transplantation, 2018, 18, 464-503.	2.6	28
126	Healthcare Costs for the Evaluation, Surgery, and Follow-Up Care of Living Kidney Donors. Transplantation, 2018, 102, 1367-1374.	0.5	16



#	ARTICLE	IF	CITATIONS
127	Prescription opioid use before and after kidney transplant: Implications for posttransplant outcomes. American Journal of Transplantation, 2018, 18, 2987-2999.	2.6	43
128	Core Assessment of Predonation Kidney Function: Clarification of the 2017 KDIGO Living Donor Guideline. American Journal of Kidney Diseases, 2018, 72, 154-155.	2.1	1
129	Potential implications of a more timely living kidney donor evaluation. American Journal of Transplantation, 2018, 18, 2719-2729.	2.6	15
130	Landscape of Living Multiorgan Donation in the United States. Transplantation, 2018, 102, 1148-1155.	0.5	10
131	The impact of direct-acting antiviral agents on liver and kidney transplant costs and outcomes. American Journal of Transplantation, 2018, 18, 2473-2482.	2.6	47
132	Duration of Living Kidney Transplant Donor Evaluations: Findings From 2 Multicenter Cohort Studies. American Journal of Kidney Diseases, 2018, 72, 483-498.	2.1	33
133	Initiating Maintenance Dialysis Before Living Kidney Donor Transplantation When a Donor Candidate Evaluation Is Well Underway. Transplantation, 2018, 102, e345-e353.	0.5	12
134	Center practice drives variation in choice of US kidney transplant induction therapy: a retrospective analysis of contemporary practice. Transplant International, 2018, 31, 198-211.	0.8	46
135	Temporal trends, center-level variation, and the impact of prevalent state obesity rates on acceptance of obese living kidney donors. American Journal of Transplantation, 2018, 18, 642-649.	2.6	23
136	Antidepressant medication use before and after kidney transplant: implications for outcomes - a retrospective study. Transplant International, 2018, 31, 20-31.	0.8	12
137	The Efficiency of Evaluating Candidates for Living Kidney Donation: A Scoping Review. Transplantation Direct, 2018, 4, e394.	0.8	18
138	Center-driven and Clinically Driven Variation in US Liver Transplant Maintenance Immunosuppression Therapy: A National Practice Patterns Analysis. Transplantation Direct, 2018, 4, e364.	0.8	16
139	Establishing a Core Outcome Measure for Graft Health. Transplantation, 2018, 102, S82.	0.5	1
140	Addressing Disparities in Living Donor Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 1909-1911.	2.2	27
141	Validation of Living Donor Nephrectomy Codes. Canadian Journal of Kidney Health and Disease, 2018, 5, 205435811876083.	0.6	5
142	Renal Function, Albuminuria, and the Risk of Cardiovascular Events After Kidney Transplantation. Transplantation Direct, 2018, 4, e389.	0.8	12
143	Current opinions in organ allocation. American Journal of Transplantation, 2018, 18, 2625-2634.	2.6	7
144	Metformin use in the first year after kidney transplant, correlates, and associated outcomes in diabetic transplant recipients: A retrospective analysis of integrated registry and pharmacy claims data. Clinical Transplantation, 2018, 32, e13302.	0.8	23

#	ARTICLE	IF	CITATIONS
145	Strategies for Increasing Knowledge, Communication, and Access to Living Donor Transplantation: an Evidence Review to Inform Patient Education. <i>Current Transplantation Reports</i> , 2018, 5, 27-44.	0.9	38
146	Follow-up Care of Living Kidney Donors in Alberta, Canada. <i>Canadian Journal of Kidney Health and Disease</i> , 2018, 5, 205435811878936.	0.6	7
147	Assessing the Attitudes and Perceptions Regarding the Use of Mobile Health Technologies for Living Kidney Donor Follow-Up: Survey Study. <i>JMIR MHealth and UHealth</i> , 2018, 6, e11192.	1.8	7
148	The Risk of Cardiovascular Disease Is Not Increasing Over Time Despite Aging and Higher Comorbidity Burden of Kidney Transplant Recipients. <i>Transplantation</i> , 2017, 101, 588-596.	0.5	58
149	Evaluation and Management of Pulmonary Hypertension in Kidney Transplant Candidates and Recipients. <i>Transplantation</i> , 2017, 101, 166-181.	0.5	37
150	Cultural competency of a mobile, customized patient education tool for improving potential kidney transplant recipients' knowledge and decision-making. <i>Clinical Transplantation</i> , 2017, 31, e12944.	0.8	37
151	The Incremental Cost of Incompatible Living Donor Kidney Transplantation: A National Cohort Analysis. <i>American Journal of Transplantation</i> , 2017, 17, 3123-3130.	2.6	25
152	The National Landscape of Living Kidney Donor Follow-Up in the United States. <i>American Journal of Transplantation</i> , 2017, 17, 3131-3140.	2.6	50
153	The Living Donor Collective: A Scientific Registry for Living Donors. <i>American Journal of Transplantation</i> , 2017, 17, 3040-3048.	2.6	45
154	Diabetes Mellitus in Living Pancreas Donors. <i>Transplantation</i> , 2017, 101, 1276-1281.	0.5	8
155	Albuminuria and posttransplant chronic kidney disease stage predict transplant outcomes. <i>Kidney International</i> , 2017, 92, 470-478.	2.6	29
156	Renal and cardiac assessment of living kidney donor candidates. <i>Nature Reviews Nephrology</i> , 2017, 13, 420-428.	4.1	13
157	Clinical and Economic Consequences of Early Cancer After Kidney Transplantation in Contemporary Practice. <i>Transplantation</i> , 2017, 101, 858-866.	0.5	21
158	Survival implications of opioid use before and after liver transplantation. <i>Liver Transplantation</i> , 2017, 23, 305-314.	1.3	63
159	Venous Thromboembolism and the Risk of Death and Graft Loss in Kidney Transplant Recipients. <i>American Journal of Nephrology</i> , 2017, 46, 343-354.	1.4	19
160	Transplant Center Volume and the Risk of Pancreas Allograft Failure. <i>Transplantation</i> , 2017, 101, 2757-2764.	0.5	43
161	Summary of Kidney Disease. <i>Transplantation</i> , 2017, 101, 1783-1792.	0.5	225
162	OPTN/SRTR 2015 Annual Data Report: Economics. <i>American Journal of Transplantation</i> , 2017, 17, 425-502.	2.6	3

#	ARTICLE	IF	CITATIONS
163	The Privilege of Induction Avoidance and Calcineurin Inhibitors Withdrawal in 2 Haplotype HLA Matched White Kidney Transplantation. <i>Transplantation Direct</i> , 2017, 3, e133.	0.8	3
164	Moving from Intuition to Data: Building the Evidence to Support and Increase Living Donor Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1383-1385.	2.2	14
165	Donation, Not Disease! A Multiple-Hit Hypothesis on Development of Post-Donation Kidney Disease. <i>Current Transplantation Reports</i> , 2017, 4, 320-326.	0.9	11
166	Selected Mildly Obese Donors Can Be Used Safely in Simultaneous Pancreas and Kidney Transplantation. <i>Transplantation</i> , 2017, 101, 1159-1166.	0.5	16
167	Predonation Prescription Opioid Use: A Novel Risk Factor for Readmission After Living Kidney Donation. <i>American Journal of Transplantation</i> , 2017, 17, 744-753.	2.6	23
168	The Changing Financial Landscape of Renal Transplant Practice: A National Cohort Analysis. <i>American Journal of Transplantation</i> , 2017, 17, 377-389.	2.6	42
169	Understanding and Communicating Medical Risks for Living Kidney Donors: A Matter of Perspective. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 12-24.	3.0	46
170	Multiple Solid Organ Donations from Live Donors in the United States: What Do We Know?. <i>Journal of the American College of Surgeons</i> , 2017, 225, e170.	0.2	0
171	KDIGO Clinical Practice Guideline on the Evaluation and Care of Living Kidney Donors. <i>Transplantation</i> , 2017, 101, S7-S105.	0.5	308
172	Outcomes of Live Kidney Donors Who Develop End-Stage Renal Disease. <i>Transplantation</i> , 2016, 100, 1306-1312.	0.5	20
173	Risk of Nephrectomy in Previous Living Kidney Donors. <i>Transplantation</i> , 2016, 100, 1313-1317.	0.5	5
174	Patterns of End-Stage Renal Disease Caused by Diabetes, Hypertension, and Glomerulonephritis in Live Kidney Donors. <i>American Journal of Transplantation</i> , 2016, 16, 3540-3547.	2.6	71
175	National Variation in Use of Immunosuppression for Kidney Transplantation: A Call for Evidence-Based Regimen Selection. <i>American Journal of Transplantation</i> , 2016, 16, 2453-2462.	2.6	46
176	Perioperative Complications After Living Kidney Donation: A National Study. <i>American Journal of Transplantation</i> , 2016, 16, 1848-1857.	2.6	105
177	Clinical and economic consequences of first-year urinary tract infections, sepsis, and pneumonia in contemporary kidney transplantation practice. <i>Transplant International</i> , 2016, 29, 241-252.	0.8	54
178	The Impact of Obesity on Allograft Failure After Kidney Transplantation. <i>Transplantation</i> , 2016, 100, 1963-1969.	0.5	40
179	Pretransplant Midodrine Use. <i>Transplantation</i> , 2016, 100, 1086-1093.	0.5	25
180	Improving Access to Liver Care Across the Continuum of Care: Opportunities and Challenges. <i>American Journal of Transplantation</i> , 2016, 16, 2777-2778.	2.6	2

#	ARTICLE	IF	CITATIONS
181	Economics. American Journal of Transplantation, 2016, 16, 169-194.	2.6	4
182	Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. Transplant International, 2016, 29, 1226-1236.	0.8	50
183	Economic Impacts of ABO-Incompatible Live Donor Kidney Transplantation: A National Study of Medicare-Insured Recipients. American Journal of Transplantation, 2016, 16, 1465-1473.	2.6	34
184	Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. New England Journal of Medicine, 2016, 374, 2093-2095.	13.9	26
185	Estimated GFR for Living Kidney Donor Evaluation. American Journal of Transplantation, 2016, 16, 171-180.	2.6	39
186	The Impact of Redistricting Proposals on Health Care Expenditures for Liver Transplant Candidates and Recipients. American Journal of Transplantation, 2016, 16, 583-593.	2.6	28
187	Recipient Outcomes Following Transplantation of Allografts From Live Kidney Donors Who Subsequently Developed End-Stage Renal Disease. American Journal of Transplantation, 2016, 16, 3532-3539.	2.6	15
188	Variation in Comedication Use According to Kidney Transplant Immunosuppressive Regimens: Application of Integrated Registry and Pharmacy Claims Data. Transplantation Proceedings, 2016, 48, 55-58.	0.3	3
189	Kidney-Failure Risk Projection for the Living Kidney-Donor Candidate. New England Journal of Medicine, 2016, 374, 411-421.	13.9	354
190	Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants. Trials, 2015, 16, 365.	0.7	30
191	Quantifying Prognostic Impact of Prescription Opioid Use Before Kidney Transplantation Through Linked Registry and Pharmaceutical Claims Data. Transplantation, 2015, 99, 187-196.	0.5	41
192	Gender differences in use of prescription narcotic medications among living kidney donors. Clinical Transplantation, 2015, 29, 927-937.	0.8	10
193	Gestational Hypertension and Preeclampsia in Living Kidney Donors. Obstetrical and Gynecological Survey, 2015, 70, 302-303.	0.2	0
194	Race, Relationship and Renal Diagnoses After Living Kidney Donation. Transplantation, 2015, 99, 1723-1729.	0.5	48
195	OPTN/SRTR 2013 Annual Data Report: Economics. American Journal of Transplantation, 2015, 15, 1-24.	2.6	14
196	Gout After Living Kidney Donation: A Matched Cohort Study. American Journal of Kidney Diseases, 2015, 65, 925-932.	2.1	45
197	Variation in Biliary Complication Rates Following Liver Transplantation: Implications for Cost and Outcome. American Journal of Transplantation, 2015, 15, 170-179.	2.6	36
198	Gestational Hypertension and Preeclampsia in Living Kidney Donors. New England Journal of Medicine, 2015, 372, 124-133.	13.9	295

#	ARTICLE	IF	CITATIONS
199	Living Donor Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1659-1669.	2.2	76
200	Gout after Living Kidney Donation: Correlations with Demographic Traits and Renal Complications. <i>American Journal of Nephrology</i> , 2015, 41, 231-240.	1.4	27
201	Gestational Hypertension and Preeclampsia in Living Kidney Donors. <i>New England Journal of Medicine</i> , 2015, 372, 1468-1470.	13.9	23
202	Long-term medical risks to the living kidney donor. <i>Nature Reviews Nephrology</i> , 2015, 11, 411-419.	4.1	63
203	Opponent's comments. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1809-1810.	0.4	0
204	Pro: Pretransplant weight loss: yes. <i>Nephrology Dialysis Transplantation</i> , 2015, 30, 1798-1803.	0.4	17
205	Associations of Pre-Transplant Prescription Narcotic Use with Clinical Complications after Kidney Transplantation. <i>American Journal of Nephrology</i> , 2015, 41, 165-176.	1.4	54
206	Assessing Transplant Education Practices in Dialysis Centers. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2015, 10, 1617-1625.	2.2	47
207	Functional Status Metrics in Kidney Transplantation: Implications for Patients, Programs, and Policy Makers. <i>American Journal of Kidney Diseases</i> , 2015, 66, 738-741.	2.1	2
208	The relevance of the FAVORIT blood pressure associations. <i>Nature Reviews Nephrology</i> , 2014, 10, 366-367.	4.1	0
209	Understanding Antihypertensive Medication Use after Living Kidney Donation through Linked National Registry and Pharmacy Claims Data. <i>American Journal of Nephrology</i> , 2014, 40, 174-183.	1.4	26
210	Assessing Variation in the Costs of Care Among Patients Awaiting Liver Transplantation. <i>American Journal of Transplantation</i> , 2014, 14, 70-78.	2.6	41
211	Risk of serious gastrointestinal bleeding in living kidney donors. <i>Clinical Transplantation</i> , 2014, 28, 530-539.	0.8	16
212	National Assessment of Early Biliary Complications After Liver Transplantation. <i>Transplantation</i> , 2014, 98, 1126-1235.	0.5	19
213	End-stage renal disease risk in live kidney donors. <i>Current Opinion in Nephrology and Hypertension</i> , 2014, 23, 592-596.	1.0	28
214	Early Clinical Complications After ABO-Incompatible Live-Donor Kidney Transplantation. <i>Transplantation</i> , 2014, 98, 54-65.	0.5	77
215	National assessment of early biliary complications following liver transplantation: Incidence and outcomes. <i>Liver Transplantation</i> , 2014, 20, 446-456.	1.3	58
216	Prognostic impact of mechanical ventilation after liver transplantation: a national database study. <i>American Journal of Surgery</i> , 2014, 208, 582-590.	0.9	24

#	ARTICLE	IF	CITATIONS
217	Clopidogrel use as a risk factor for poor outcomes after kidney transplantation. American Journal of Surgery, 2014, 208, 556-562.	0.9	6
218	Accountability for end-stage organ care: Implications of geographic variation in access to kidney transplantation. Surgery, 2014, 155, 734-742.	1.0	29
219	Consistency of Racial Variation in Medical Outcomes Among Publicly and Privately Insured Living Kidney Donors. Transplantation, 2014, 97, 316-324.	0.5	38
220	Preoperative Cardiovascular Evaluation and Management. , 2014, , 93-110.		0
221	Addressing Geographic Disparities in Liver Transplantation Through Redistricting. American Journal of Transplantation, 2013, 13, 2052-2058.	2.6	142
222	Clinical correlates, outcomes and healthcare costs associated with early mechanical ventilation after kidney transplantation. American Journal of Surgery, 2013, 206, 686-692.	0.9	2
223	Health-related quality of life in kidney transplant patients with diabetes. Clinical Transplantation, 2013, 27, E554-62.	0.8	13
224	Understanding Medical Care of Transplant Recipients through Integrated Registry and Pharmacy Claims Data. American Journal of Nephrology, 2013, 38, 420-429.	1.4	10
225	Improving access to liver transplantation: Another part of the puzzle. Liver Transplantation, 2013, 19, 353-354.	1.3	0
226	The cost implications of first anniversary renal function after living, standard criteria deceased and expanded criteria deceased donor kidney transplantation. Journal of Medical Economics, 2013, 16, 75-84.	1.0	12
227	Better Understanding Live Donor Risk through Big Data. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1645-1647.	2.2	14
228	Risk of Kidney Stones With Surgical Intervention in Living Kidney Donors. American Journal of Transplantation, 2013, 13, 2935-2944.	2.6	30
229	Health outcomes among non-Caucasian living kidney donors: knowns and unknowns. Transplant International, 2013, 26, 853-864.	0.8	38
230	Transplant Certification and Quality Assessment: Time to Take the Front Line?. Progress in Transplantation, 2013, 23, 206-212.	0.4	4
231	715. Critical Care Medicine, 2013, 41, A176.	0.4	0
232	565. Critical Care Medicine, 2013, 41, A138.	0.4	0
233	Following the Organ Supply. Transplantation, 2013, 95, 361-371.	0.5	34
234	Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. Circulation, 2012, 126, 617-663.	1.6	255

#	ARTICLE	IF	CITATIONS
235	Obesity and Kidney Transplant Candidates: How Big Is Too Big for Transplantation?. American Journal of Nephrology, 2012, 36, 575-586.	1.4	124
236	Acute dialysis risk in living kidney donors. Nephrology Dialysis Transplantation, 2012, 27, 3291-3295.	0.4	32
237	Geographically Equitable Liver Allocation Using Mathematical Redistricting. Transplantation, 2012, 94, 521.	0.5	0
238	Use of 12-Month Renal Function and Baseline Clinical Factors to Predict Long-Term Graft Survival. Transplantation, 2012, 93, 172-181.	0.5	40
239	Cancer Diagnoses After Living Kidney Donation. Transplantation, 2012, 94, 139-144.	0.5	26
240	Depression Diagnoses After Living Kidney Donation. Transplantation, 2012, 94, 77-83.	0.5	68
241	The Implications of Acute Rejection and Reduced Allograft Function on Health Care Expenditures in Contemporary US Kidney Transplantation. Transplantation, 2012, 94, 241-249.	0.5	39
242	The Implications of Acute Rejection for Allograft Survival in Contemporary U.S. Kidney Transplantation. Transplantation, 2012, 94, 369-376.	0.5	51
243	Geographically Equitable Liver Allocation Using Mathematical Redistricting. Transplantation, 2012, 94, 89.	0.5	0
244	Lupus-like glomerulonephritis: an autoimmune complication of hepatitis C infection. CEN Case Reports, 2012, 1, 29-33.	0.5	3
245	Cardiac Catheterization in the Dialysis Population in 2012: We Know More, but Much Remains Unknown. Seminars in Dialysis, 2012, 25, 257-262.	0.7	1
246	Cardiac Disease Evaluation and Management Among Kidney and Liver Transplantation Candidates. Journal of the American College of Cardiology, 2012, 60, 434-480.	1.2	328
247	PDB71 Health Related Quality of Life in Kidney Transplant Patients With Diabetes. Value in Health, 2012, 15, A183.	0.1	0
248	Risks and Outcomes of Living Donation. Advances in Chronic Kidney Disease, 2012, 19, 220-228.	0.6	81
249	Renal function following living, standard criteria deceased and expanded criteria deceased donor kidney transplantation: impact on graft failure and death. Transplant International, 2012, 25, 179-191.	0.8	24
250	Preparing Potential Living Kidney Donors for What They Will Experience Emotionally. American Journal of Kidney Diseases, 2012, 60, 1-2.	2.1	3
251	Predicting long-term graft survival in adult kidney transplant recipients. Saudi Journal of Kidney Diseases and Transplantation: an Official Publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2012, 23, 693.	0.4	2
252	Costs and Outcomes of Privately-Insured Kidney Transplant Recipients by Body Mass Index. Journal of Nephrology & Therapeutics, 2012, 01, .	0.1	8

#	ARTICLE	IF	CITATIONS
253	Renal Dysfunction in Liver Transplant Candidates: Evaluation, Classification and Management in Contemporary Practice. <i>Journal of Nephrology &amp; Therapeutics</i> , 2012, 01, .	0.1	2
254	The Role of the Crossmatch in Kidney Transplantation: Past, Present and Future. <i>Journal of Nephrology &amp; Therapeutics</i> , 2012, 01, .	0.1	1
255	Kidney transplant Medicare payments and length of stay: associations with comorbidities and organ quality. <i>Archives of Medical Science</i> , 2011, 2, 278-286.	0.4	34
256	Associations of Renal Function at 1-Year After Kidney Transplantation With Subsequent Return to Dialysis, Mortality, and Healthcare Costs. <i>Transplantation</i> , 2011, 91, 1347-1356.	0.5	52
257	Cardioprotective Medication Use After Acute Myocardial Infarction in Kidney Transplant Recipients. <i>Transplantation</i> , 2011, 91, 1120-1126.	0.5	14
258	Associations of Recipient Illness History With Hypertension and Diabetes After Living Kidney Donation. <i>Transplantation</i> , 2011, 91, 1227-1232.	0.5	6
259	The Economic Implications of Broader Sharing of Liver Allografts. <i>American Journal of Transplantation</i> , 2011, 11, 798-807.	2.6	42
260	MELD Exceptions and Rates of Waiting List Outcomes. <i>American Journal of Transplantation</i> , 2011, 11, 2362-2371.	2.6	179
261	Living Kidney Donor Follow-Up: State-of-the-Art and Future Directions, Conference Summary and Recommendations. <i>American Journal of Transplantation</i> , 2011, 11, 2561-2568.	2.6	91
262	Joint Association of Hyperuricemia and Reduced GFR on Cardiovascular Morbidity: A Historical Cohort Study Based on Laboratory and Claims Data From a National Insurance Provider. <i>American Journal of Kidney Diseases</i> , 2011, 58, 398-408.	2.1	37
263	The interaction among donor characteristics, severity of liver disease, and the cost of liver transplantation. <i>Liver Transplantation</i> , 2011, 17, 233-242.	1.3	92
264	Interpreting Body Composition in Kidney Transplantation: Weighing Candidate Selection, Prognostication, and Interventional Strategies to Optimize Health. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2011, 6, 1238-1240.	2.2	18
265	The economic impact of addressing the organ shortage with clinically high-risk allografts. <i>Missouri Medicine</i> , 2011, 108, 275-9.	0.3	7
266	Reply: Liver transplantation costs in the era of a health care crisis. <i>Liver Transplantation</i> , 2010, 16, 535-535.	1.3	0
267	Cardiovascular Risk Assessment Among Potential Kidney Transplant Candidates: Approaches and Controversies. <i>American Journal of Kidney Diseases</i> , 2010, 55, 152-167.	2.1	87
268	Immune-complex deposits in "pauci-immune" glomerulonephritis: a and brief review of recent literature. <i>Archives of Medical Science</i> , 2010, 4, 633-637.	0.4	5
269	The Interplay of Socioeconomic Status, Distance to Center, and Interdonor Service Area Travel on Kidney Transplant Access and Outcomes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 2276-2288.	2.2	194
270	Renal Function and Healthcare Costs in Patients with Polycystic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2010, 5, 1471-1479.	2.2	45



#	ARTICLE	IF	CITATIONS
271	Racial Variation in Medical Outcomes among Living Kidney Donors. <i>New England Journal of Medicine</i> , 2010, 363, 724-732.	13.9	261
272	16-P: Good Antibody or Bad Antibody?. <i>Human Immunology</i> , 2010, 71, S30.	1.2	0
273	The Clinical Importance of Flow Cytometry Crossmatch in the Context of CDC Crossmatch Results. <i>Transplantation Proceedings</i> , 2010, 42, 3471-3474.	0.3	34
274	Incidence, Predictors, Costs, and Outcome of Renal Cell Carcinoma After Kidney Transplantation: USRDS Experience. <i>Transplantation</i> , 2010, 90, 898-904.	0.5	23
275	Incidence, Predictors, and Associated Outcomes of Prostatism after Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 329-336.	2.2	33
276	Incidence, predictors and associated outcomes of rhabdomyolysis after kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 3861-3866.	0.4	19
277	Incidence, Predictors and Outcomes of Transplant Renal Artery Stenosis after Kidney Transplantation: Analysis of USRDS. <i>American Journal of Nephrology</i> , 2009, 30, 459-467.	1.4	133
278	Sensitivity of Billing Claims for Cardiovascular Disease Events among Kidney Transplant Recipients. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1213-1221.	2.2	40
279	Incremental Value of the Pancreas Allograft to the Survival of Simultaneous Pancreas-Kidney Transplant Recipients. <i>Diabetes Care</i> , 2009, 32, 600-602.	4.3	38
280	Predictive Ability of Pretransplant Comorbidities to Predict Long-Term Graft Loss and Death. <i>American Journal of Transplantation</i> , 2009, 9, 494-505.	2.6	51
281	The Cost and Quality Paradox. <i>American Journal of Transplantation</i> , 2009, 9, 985-986.	2.6	7
282	Transplant Outcomes and Economic Costs Associated with Patient Noncompliance to Immunosuppression. <i>American Journal of Transplantation</i> , 2009, 9, 2597-2606.	2.6	295
283	Liver transplantation cost in the model for end-stage liver disease era: Looking beyond the transplant admission. <i>Liver Transplantation</i> , 2009, 15, 1270-1277.	1.3	80
284	Recognition of downhill esophageal varices in hemodialysis patients requires a high index of clinical suspicion. <i>Clinical and Experimental Nephrology</i> , 2009, 13, 677-678.	0.7	5
285	The role of positive flow cytometry crossmatch in late renal allograft loss. <i>Human Immunology</i> , 2009, 70, 502-505.	1.2	21
286	40-P: Patient factors associated with selection for kidney transplantation with positive CDC crossmatch. <i>Human Immunology</i> , 2009, 70, S31.	1.2	0
287	The impact of kidney transplantation on heart failure risk varies with candidate body mass index. <i>American Heart Journal</i> , 2009, 158, 972-982.	1.2	33
288	Bariatric Surgery Among Kidney Transplant Candidates and Recipients: Analysis of the United States Renal Data System and Literature Review. <i>Transplantation</i> , 2009, 87, 1167-1173.	0.5	139

#	ARTICLE	IF	CITATIONS
289	Increasing Incidence of New-Onset Diabetes After Transplant Among Pediatric Renal Transplant Patients. <i>Transplantation</i> , 2009, 88, 367-373.	0.5	26
290	Early Outcomes of Thymoglobulin and Basiliximab Induction in Kidney Transplantation: Application of Statistical Approaches to Reduce Bias in Observational Comparisons. <i>Transplantation</i> , 2009, 87, 1520-1529.	0.5	51
291	Delivery patterns of recommended chronic kidney disease care in clinical practice: administrative claims-based analysis and systematic literature review. <i>Clinical and Experimental Nephrology</i> , 2008, 12, 41-52.	0.7	50
292	Incidence and Risk Factors for Diarrhea Following Kidney Transplantation and Association With Graft Loss and Mortality. <i>American Journal of Kidney Diseases</i> , 2008, 51, 478-486.	2.1	140
293	Association of Lower Costs of Pulsatile Machine Perfusion in Renal Transplantation from Expanded Criteria Donors. <i>American Journal of Transplantation</i> , 2008, 8, 2391-2401.	2.6	68
294	Income-Related Disparities in Kidney Transplant Graft Failures Are Eliminated by Medicare's Immunosuppression Coverage. <i>American Journal of Transplantation</i> , 2008, 8, 2636-2646.	2.6	55
295	The Promise and Pitfalls of Transplant Centers. <i>American Journal of Transplantation</i> , 2008, 8, 2179-2180.	2.6	4
296	Heart Failure Risk before and after Kidney Transplantation: Importance of Body Mass Index. <i>Journal of Cardiac Failure</i> , 2008, 14, S83.	0.7	0
297	Formation of downhill esophageal varices as a rare but serious complication of hemodialysis access: a case report and comprehensive literature review. <i>Clinical and Experimental Nephrology</i> , 2008, 12, 407-415.	0.7	27
298	Infective endocarditis in haemodialysis patients: 16-year experience at one institution. <i>CKJ: Clinical Kidney Journal</i> , 2008, 1, 253-256.	1.4	7
299	Variations in the Risk for Cerebrovascular Events after Kidney Transplant Compared with Experience on the Waiting List and after Graft Failure. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1090-1101.	2.2	75
300	Cardiac Evaluation before Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 1115-1124.	2.2	44
301	Assessment of Racial Disparities in Chronic Kidney Disease Stage 3 and 4 Care in the Department of Defense Health System. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 442-449.	2.2	38
302	Novel Methods for Tracking Long-Term Maintenance Immunosuppression Regimens. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 117-124.	2.2	11
303	Increased Risk of Graft Failure in Kidney Transplant Recipients After a Diagnosis of Dyspepsia or Gastroesophageal Reflux Disease. <i>Transplantation</i> , 2008, 85, 344-352.	0.5	9
304	Obesity and Cardiac Risk After Kidney Transplantation: Experience at One Center and Comprehensive Literature Review. <i>Transplantation</i> , 2008, 86, 303-312.	0.5	79
305	Progressive Multifocal Leukoencephalopathy and Use of Mycophenolate Mofetil After Kidney Transplantation. <i>Transplantation</i> , 2008, 86, 1474-1478.	0.5	121
306	Flow cytometry crossmatch before kidney transplantation in contemporary practice: target cell utilization, results patterns, and associated long-term graft survival. <i>Clinical Transplants</i> , 2008, , 253-66.	0.2	6

#	ARTICLE	IF	CITATIONS
307	Influence of Early Posttransplantation Prednisone and Calcineurin Inhibitor Dosages on the Incidence of New-Onset Diabetes. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 517-523.	2.2	31
308	Diabetic Complications Associated With New-Onset Diabetes Mellitus in Renal Transplant Recipients. <i>Transplantation</i> , 2007, 83, 1027-1034.	0.5	122
309	The impact of human leukocyte antigen matching on transplant complications and immunosuppression dosage. <i>Human Immunology</i> , 2007, 68, 491-499.	1.2	22
310	Health insurance considerations for adolescent transplant recipients as they transition to adulthood. <i>Pediatric Transplantation</i> , 2007, 11, 127-131.	0.5	47
311	Lack of Interventional Studies in Renal Transplant Candidates with Elevated Cardiovascular Risk. <i>American Journal of Transplantation</i> , 2007, 7, 493-494.	2.6	6
312	Patient and Graft Survival Implications of Simultaneous Pancreas Kidney Transplantation From Old Donors. <i>American Journal of Transplantation</i> , 2007, 7, 1561-1571.	2.6	75
313	A Retrospective Analysis of Immunosuppression Compliance, Dose Reduction and Discontinuation in Kidney Transplant Recipients. <i>American Journal of Transplantation</i> , 2007, 7, 2704-2711.	2.6	157
314	41-OR. <i>Human Immunology</i> , 2006, 67, S39.	1.2	0
315	Mycophenolate Mofetil Dose Reductions and Discontinuations after Gastrointestinal Complications Are Associated with Renal Transplant Graft Failure. <i>Transplantation</i> , 2006, 82, 102-107.	0.5	142
316	Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients. <i>Clinical and Experimental Nephrology</i> , 2006, 10, 55-62.	0.7	13
317	Use of $\beta$ -Blockers and Aspirin After Myocardial Infarction by Patient Renal Function in the Department of Defense Health Care System. <i>American Journal of Kidney Diseases</i> , 2006, 47, 593-603.	2.1	15
318	Is there a correlation between atherosclerosis and renal resistive indices in kidney transplant recipients?. <i>Nature Clinical Practice Nephrology</i> , 2006, 2, 64-65.	2.0	1
319	Incidence, Predictors, and Associated Outcomes of Atrial Fibrillation after Kidney Transplantation. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2006, 1, 288-296.	2.2	63
320	Agreement of Immunosuppression Regimens Described in Medicare Pharmacy Claims with the Organ Procurement and Transplantation Network Survey. <i>Journal of the American Society of Nephrology: JASN</i> , 2006, 17, 2299-2306.	3.0	25
321	Maintenance Immunosuppression Use and the Associated Risk of Avascular Necrosis After Kidney Transplantation in the United States. <i>Transplantation</i> , 2005, 79, 330-336.	0.5	27
322	The Cost Effectiveness of Deceased Organ Donation. <i>Transplantation</i> , 2005, 80, 1636-1637.	0.5	39
323	De Novo Congestive Heart Failure After Kidney Transplantation: A Common Condition With Poor Prognostic Implications. <i>American Journal of Kidney Diseases</i> , 2005, 46, 720-733.	2.1	110
324	The Life-Years Saved by a Deceased Organ Donor. <i>American Journal of Transplantation</i> , 2005, 5, 2289-2296.	2.6	118

#	ARTICLE	IF	CITATIONS
325	Incidence and Predictors of Myocardial Infarction after Kidney Transplantation. Journal of the American Society of Nephrology: JASN, 2005, 16, 496-506.	3.0	307
326	Variability in the use of thromboprophylaxis and outcomes in critically ill medical patients. American Journal of Medicine, 2005, 118, 1373-1380.	0.6	13
327	Impact of Diabetes and Hepatitis after Kidney Transplantation on Patients Who Are Affected by Hepatitis C Virus. Journal of the American Society of Nephrology: JASN, 2004, 15, 3166-3174.	3.0	82
328	Diabetic muscle infarction in end-stage renal disease. Nephrology Dialysis Transplantation, 2004, 19, 664-669.	0.4	27
329	Statin use after renal transplantation: a systematic quality review of trial-based evidence. Nephrology Dialysis Transplantation, 2004, 19, 2378-2386.	0.4	42
330	The Impact of Transplantation with Deceased Donor Hepatitis C-Positive Kidneys on Survival in Wait-Listed Long-term Dialysis Patients. American Journal of Transplantation, 2004, 4, 2032-2037.	2.6	130
331	New insights into protein intake and progression of renal disease. Current Opinion in Nephrology and Hypertension, 2004, 13, 333-336.	1.0	59
332	A developmentally regulated chromosomal origin of replication uses essential transcription elements.. Genes and Development, 1995, 9, 1543-1557.	2.7	71
333	Predictors of Transplant Outcomes. , 0, , 561-573.		0